GET DAILY SIGNALSVeradermics (MANE) $170 Target Points to +24% Upside Ahead of Key Data
Key Takeaways
- The central target of $170 is the arithmetic mean of five verified analyst price targets, rounded from $169.20.
- Veradermics, Incorporated recently traded near $136.66, implying a roughly 24% move to reach the target — a substantial, not modest, gap.
- The five targets used range from $160 to $182; a broader S&P Global survey of seven analysts averages about $163.50 with a $135–$182 range.
- Support rests on the upcoming Phase 3 readout for lead hair-loss candidate VDPHL01 and a cash runway into 2030.
- The biggest risks are that the company is pre-revenue, still loss-making, and highly volatile, with meaningful short interest.
Understanding the $170 Consensus Target
Veradermics, Incorporated (MANE) is a late clinical-stage biopharmaceutical company developing novel treatments for dermatologic and aesthetic conditions, led by oral, non-hormonal hair-loss candidate VDPHL01. As a development-stage drugmaker with no product revenue, its valuation and analyst targets hinge heavily on clinical catalysts rather than current earnings.
Five recent, attributed targets form the basis of the $170 central figure: Citi analyst Geoff Meacham at $160 (maintained in September and October 2026), Jefferies at $182 (September 2026), Needham at $164 (August 2026), LifeSci Capital at $170 (August 2026), and B. Riley Securities at $170 (initiated July 2026). Their arithmetic mean is $169.20, rounded to $170. For context, S&P Global's broader seven-analyst aggregate carries an average price target near $163.50 and a Strong Buy consensus rating, with estimates spanning roughly $135 to $182.
The spread between $160 and $182 reflects genuine disagreement about how much credit to give VDPHL01 ahead of data. Bullish analysts emphasize the favorable risk-reward into the Study 304 readout and the company's long cash runway, while more conservative targets discount for execution and clinical risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where MANE Stands Today and the Road to $170
MANE last traded around $136.66, near the top of a 52-week range of $32.00 to $139.12, following a powerful advance from its February 2026 IPO price of $17. Reaching $170 would require a gain of about 24% from current levels, which is substantial for any equity and especially demanding for a pre-commercial biotech that has already repriced sharply upward.
The most likely path toward that level runs through the Phase 3 topline data for VDPHL01 in male pattern hair loss, expected in the November-to-December 2026 window. Because the company reports no meaningful revenue and widening net losses, the near-term share price is driven by sentiment, trial outcomes, and analyst revisions rather than conventional earnings growth.
Key Factors That Could Drive the Stock Higher
- The pending Study 304 Phase 3 readout is a discrete, high-impact catalyst; analysts cite strong prior Study 302 results and a similar trial design as reasons for confidence.
- A cash position reported near $820 million and management's guidance of a runway into 2030 reduce near-term dilution risk.
- A pipeline beyond VDPHL01 — including programs for common warts, alopecia areata, and molluscum contagiosum — offers optionality.
- Upward analyst revisions and a unanimous Buy/Strong Buy stance have accompanied the rally, reinforcing positive sentiment.
Risks That Might Keep the Target Out of Reach
- Negative or disappointing Phase 3 data would be a severe setback, since VDPHL01 underpins most of the current valuation.
- The company is pre-commercial with no product sales and widening losses, leaving the stock sensitive to any perceived funding or timeline risk.
- Extremely high volatility and elevated short interest near 15% of the float can amplify drawdowns on any negative news.
- Valuation is difficult to anchor with traditional metrics because there is no meaningful revenue or EPS (earnings per share) to support a price-to-earnings comparison.
Technical Picture and Key Levels to Watch
MANE has been in a strong uptrend since its IPO, but the steepness of that move leaves limited established support. The 52-week high near $139 acts as the immediate resistance zone that bulls would need to clear before a push toward $170. Below the current price, reference support areas include the prior consolidation band near $108–$110 and a lower zone near $98, both visible during the stock's 2026 pullbacks. A decisive break above the $139 area, sustained on volume, would be the clearest technical confirmation of an extended advance.
Investment Timeframe and What to Monitor Next
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may differ and the true driver here is event-driven rather than calendar-driven. The critical item to monitor is the Phase 3 Study 304 data for VDPHL01, expected in November or December 2026. Investors should also watch the next quarterly earnings report, estimated around November 12, 2026, along with analyst target revisions, any update to the cash runway, and FDA (Food and Drug Administration) or clinical timeline commentary.
AI Daily Buy/Sell Signals
For traders who prefer a data-driven, real-time view of shifting momentum, Tickeron's AI Daily Buy/Sell Signals offer a practical complement to fundamental research. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. I find these signals helpful for spotting changes in momentum around event-driven names like this one. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for MANE turns positive, indicating new upward trend
MANE saw its Momentum Indicator move above the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator turned positive. In 13 of the 14 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MANE just turned positive on October 20, 2026. Looking at past instances where MANE's MACD turned positive, the stock continued to rise in 6 of 6 cases over the following month. The odds of a continued upward trend are 90%.
MANE moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MANE crossed bullishly above the 50-day moving average on September 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +11.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MANE advanced for three days, in 38 of 43 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 26 of 27 cases where MANE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for MANE moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 6 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MANE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
MANE broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.018) is normal, around the industry mean (2.988). P/E Ratio (-54.748) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. MANE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MANE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement